SE462364B - Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos - Google Patents
Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenosInfo
- Publication number
- SE462364B SE462364B SE8803472A SE8803472A SE462364B SE 462364 B SE462364 B SE 462364B SE 8803472 A SE8803472 A SE 8803472A SE 8803472 A SE8803472 A SE 8803472A SE 462364 B SE462364 B SE 462364B
- Authority
- SE
- Sweden
- Prior art keywords
- cells
- gamma interferon
- smooth muscle
- gamma
- interferon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Radiation-Therapy Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8803472A SE462364B (sv) | 1988-09-30 | 1988-09-30 | Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos |
IL9179689A IL91796A (en) | 1988-09-30 | 1989-09-27 | Pharmacological preparations containing gamma interferon |
PCT/SE1989/000520 WO1990003189A1 (en) | 1988-09-30 | 1989-09-27 | Use of gamma-interferon for the treatment of vascular stenosis |
AT89850317T ATE86869T1 (de) | 1988-09-30 | 1989-09-27 | Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose. |
US07/671,786 US5208019A (en) | 1988-09-30 | 1989-09-27 | Use of gamma-interferon for the treatment of vascular stenosis |
KR1019900701144A KR0137017B1 (ko) | 1988-09-30 | 1989-09-27 | 감마-인터페론을 이용한 혈관 협착증의 치료방법 |
EP89850317A EP0367735B1 (en) | 1988-09-30 | 1989-09-27 | Use of gamma interferon in pharmaceutical preparations for the treatment of vascular stenosis |
AU43051/89A AU623181B2 (en) | 1988-09-30 | 1989-09-27 | Use of gamma-interferon for the treatment of vascular stenosis |
DE89850317T DE68905438T2 (de) | 1988-09-30 | 1989-09-27 | Verwendung von Interferon-gamma in pharmazeutischen Zubereitungen zur Behandlung von Gefässstenose. |
HU895542A HU206988B (en) | 1988-09-30 | 1989-09-27 | Process for producing pharmaceutical composition comprising gamma-interferon as active ingredient |
JP1510051A JP2895896B2 (ja) | 1988-09-30 | 1989-09-27 | 脈管狭窄の治療におけるγ―インターフェロンの使用 |
DD89333072A DD288094A5 (de) | 1988-09-30 | 1989-09-28 | Verwendung von gamma-interferon zur behandlung von gefaessverengungen |
NZ230816A NZ230816A (en) | 1988-09-30 | 1989-09-28 | Gamma interferon, treatment of vascular stenosis |
CA000614859A CA1338722C (en) | 1988-09-30 | 1989-09-29 | Gamma-interferon for the treatment of vascular stenosis |
PH39308A PH26293A (en) | 1988-09-30 | 1989-09-29 | Use of gamma-interferon for the treatment of vascular stenosis |
PT91863A PT91863B (pt) | 1988-09-30 | 1989-09-29 | Processo de preparacao de uma preparacao farmaceutica a base de gama-interferao |
IE312389A IE63874B1 (en) | 1988-09-30 | 1989-09-29 | Use of gamma-interferon for the treatment of vascular stenosis |
DK199100562A DK174523B1 (da) | 1988-09-30 | 1991-03-27 | Anvendelse af gamma-interferon til fremstilling af et lægemiddel til behandling af vasculær stenosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8803472A SE462364B (sv) | 1988-09-30 | 1988-09-30 | Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos |
Publications (2)
Publication Number | Publication Date |
---|---|
SE8803472D0 SE8803472D0 (sv) | 1988-09-30 |
SE462364B true SE462364B (sv) | 1990-06-18 |
Family
ID=20373494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE8803472A SE462364B (sv) | 1988-09-30 | 1988-09-30 | Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos |
Country Status (18)
Country | Link |
---|---|
US (1) | US5208019A (ja) |
EP (1) | EP0367735B1 (ja) |
JP (1) | JP2895896B2 (ja) |
KR (1) | KR0137017B1 (ja) |
AT (1) | ATE86869T1 (ja) |
AU (1) | AU623181B2 (ja) |
CA (1) | CA1338722C (ja) |
DD (1) | DD288094A5 (ja) |
DE (1) | DE68905438T2 (ja) |
DK (1) | DK174523B1 (ja) |
HU (1) | HU206988B (ja) |
IE (1) | IE63874B1 (ja) |
IL (1) | IL91796A (ja) |
NZ (1) | NZ230816A (ja) |
PH (1) | PH26293A (ja) |
PT (1) | PT91863B (ja) |
SE (1) | SE462364B (ja) |
WO (1) | WO1990003189A1 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
EP0671954A1 (en) * | 1992-02-05 | 1995-09-20 | Thomas Jefferson University | Interferon gene therapy for the treatment of vascular disorders |
US6306421B1 (en) | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6395494B1 (en) | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US5770609A (en) * | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US5957972A (en) * | 1992-09-29 | 1999-09-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Implants possessing a surface of endothelial cells genetically-modified to inhibit intimal thickening |
CA2153158A1 (en) * | 1993-01-07 | 1994-07-21 | Andrew Zalewski | Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5595722A (en) * | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6663881B2 (en) | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6197789B1 (en) | 1995-06-07 | 2001-03-06 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
CA2162586C (en) * | 1993-05-13 | 2006-01-03 | David J. Grainger | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
US6323184B1 (en) | 1993-10-15 | 2001-11-27 | Thomas Jefferson University | Arteriovenous and venous graft treatments: methods and compositions |
US6133242A (en) * | 1993-10-15 | 2000-10-17 | Thomas Jefferson Univerisity | Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes |
US5449679A (en) * | 1994-07-29 | 1995-09-12 | Leonard; Robert J. | Process and products for reducing biological fluid levels of a lipid soluble waste |
US5665591A (en) * | 1994-12-06 | 1997-09-09 | Trustees Of Boston University | Regulation of smooth muscle cell proliferation |
US7611533B2 (en) * | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
WO1997018831A1 (fr) * | 1995-11-17 | 1997-05-29 | Toray Industries, Inc. | Protection des cellules endotheliales |
US5681558A (en) * | 1995-11-30 | 1997-10-28 | Berlex Laboratories, Inc. | Method of using beta-interferons to treat restenosis |
ES2314786T3 (es) | 1998-04-02 | 2009-03-16 | Genentech, Inc. | Uso de interferon gamma para el tratamiento de la hipertrofia cardiaca. |
US7524826B2 (en) * | 2000-04-14 | 2009-04-28 | Mcmaster University And Hamilton Health Sciences Corporation | Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque |
WO2002089828A2 (en) * | 2001-05-04 | 2002-11-14 | Institute Of Molecular And Cell Biology | Interferons in the treatment of ischemia |
NZ548256A (en) | 2004-02-02 | 2010-02-26 | Ambrx Inc | Modified human four helical bundle polypeptides and their uses |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE11014T1 (de) * | 1981-07-14 | 1985-01-15 | Efamol Limited | Pharmazeutische und diaetetische zusammensetzung zur erhoehung der serie-l-pg-produktion. |
US5096705A (en) * | 1981-10-19 | 1992-03-17 | Genentech, Inc. | Human immune interferon |
US4454115A (en) * | 1981-10-23 | 1984-06-12 | Wisconsin Alumni Research Foundation | Method of reducing the level of low density lipoproteins in the serum of a patient |
US4483849A (en) * | 1983-01-07 | 1984-11-20 | Carter William A | Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product |
JPS6069037A (ja) * | 1983-09-26 | 1985-04-19 | Sunstar Inc | エリテマト−デス治療用外用剤 |
US4680175A (en) * | 1984-02-07 | 1987-07-14 | Interferon Sciences, Inc. | Interferon administration vehicles |
US4605555A (en) * | 1984-09-20 | 1986-08-12 | Sun Star Kabushiki Kaisha | Composition and method for treating keratosic disorder of skin and mucosa |
US4946674A (en) * | 1984-10-05 | 1990-08-07 | Bioferon Biochemische Substanzen Gmbh & Co. | Process for treatment of rheumatic diseases |
IL78444A (en) * | 1986-04-08 | 1992-05-25 | Yeda Res & Dev | Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody |
US5026544A (en) * | 1988-02-16 | 1991-06-25 | Board Of Reagents, The University Of Texas System | Methods and compositions for inhibiting the growth of neoplastic cells |
-
1988
- 1988-09-30 SE SE8803472A patent/SE462364B/sv not_active IP Right Cessation
-
1989
- 1989-09-27 HU HU895542A patent/HU206988B/hu not_active IP Right Cessation
- 1989-09-27 AT AT89850317T patent/ATE86869T1/de not_active IP Right Cessation
- 1989-09-27 AU AU43051/89A patent/AU623181B2/en not_active Expired
- 1989-09-27 EP EP89850317A patent/EP0367735B1/en not_active Expired - Lifetime
- 1989-09-27 DE DE89850317T patent/DE68905438T2/de not_active Expired - Lifetime
- 1989-09-27 WO PCT/SE1989/000520 patent/WO1990003189A1/en active Application Filing
- 1989-09-27 IL IL9179689A patent/IL91796A/en not_active IP Right Cessation
- 1989-09-27 KR KR1019900701144A patent/KR0137017B1/ko not_active IP Right Cessation
- 1989-09-27 JP JP1510051A patent/JP2895896B2/ja not_active Expired - Lifetime
- 1989-09-27 US US07/671,786 patent/US5208019A/en not_active Expired - Lifetime
- 1989-09-28 DD DD89333072A patent/DD288094A5/de unknown
- 1989-09-28 NZ NZ230816A patent/NZ230816A/en unknown
- 1989-09-29 PT PT91863A patent/PT91863B/pt not_active IP Right Cessation
- 1989-09-29 PH PH39308A patent/PH26293A/en unknown
- 1989-09-29 CA CA000614859A patent/CA1338722C/en not_active Expired - Lifetime
- 1989-09-29 IE IE312389A patent/IE63874B1/en not_active IP Right Cessation
-
1991
- 1991-03-27 DK DK199100562A patent/DK174523B1/da not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
SE8803472D0 (sv) | 1988-09-30 |
AU4305189A (en) | 1990-04-18 |
PH26293A (en) | 1992-04-10 |
JP2895896B2 (ja) | 1999-05-24 |
WO1990003189A1 (en) | 1990-04-05 |
IE63874B1 (en) | 1995-06-14 |
KR900701308A (ko) | 1990-12-01 |
EP0367735B1 (en) | 1993-03-17 |
DD288094A5 (de) | 1991-03-21 |
PT91863A (pt) | 1990-03-30 |
ATE86869T1 (de) | 1993-04-15 |
NZ230816A (en) | 1997-06-24 |
KR0137017B1 (ko) | 1998-04-25 |
HU895542D0 (en) | 1991-10-28 |
DK174523B1 (da) | 2003-05-12 |
PT91863B (pt) | 1995-05-31 |
CA1338722C (en) | 1996-11-19 |
IE893123L (en) | 1990-03-30 |
EP0367735A1 (en) | 1990-05-09 |
DE68905438T2 (de) | 1993-09-30 |
US5208019A (en) | 1993-05-04 |
AU623181B2 (en) | 1992-05-07 |
DK56291A (da) | 1991-05-24 |
HUT57063A (en) | 1991-11-28 |
HU206988B (en) | 1993-03-01 |
JPH04500966A (ja) | 1992-02-20 |
IL91796A (en) | 1994-10-07 |
IL91796A0 (en) | 1990-06-10 |
DK56291D0 (da) | 1991-03-27 |
DE68905438D1 (de) | 1993-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE462364B (sv) | Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos | |
Hansson et al. | Gamma-interferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and in vitro. | |
JP3854307B2 (ja) | 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害 | |
Murthy et al. | The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats | |
CA2633660A1 (en) | Method for treating symptoms of diabetes | |
Hruby et al. | Antiserum against tumor necrosis factor-alpha and a protease inhibitor reduce immune glomerular injury | |
JP2009024026A (ja) | 血管形成的に有効なfgf−2の単位用量および使用方法 | |
Ahrén et al. | Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man | |
US20070299002A1 (en) | Alpha1-Acid Glycoprotein for the Treatment of Diabetes | |
Huynh et al. | Adiponectin has a pivotal role in the cardioprotective effect of CP‐3 (iv), a selective CD36 azapeptide ligand, after transient coronary artery occlusion in mice | |
EP1358888A1 (en) | The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis | |
US6060449A (en) | Neovascularization inhibitor containing tissue factor pathway inhibitor | |
EP0408677B1 (en) | Increasing c1 inhibitor concentrations using interferon gamma alone or in combination with interleukin-6 | |
CA2100876A1 (en) | Anti-growth factor antibodies in the treatment of vascular stenosis | |
JP2008031179A (ja) | β−インターフェロンを使用して再狭窄を治療する方法 | |
MacIntyre | Calcitonin: a review of its discovery and an account of purification and action | |
JPH02209812A (ja) | 乾癬治療用医薬組成物 | |
US20060275303A1 (en) | Modulating angiogenesis using LL-37/HCAP-18 | |
JPH03500660A (ja) | 血管閉塞抑制剤 | |
JPS60501558A (ja) | インタ−フエロン感受性疾病の治療方法およびγ−インタ−フエロン含有製剤の製造方法および装置 | |
Kadowaki et al. | The effect of hypercholesterolemia on early atherosclerotic lesions initiated by fibrinopeptide B | |
JPH09124506A (ja) | 組織因子凝固系インヒビター含有動脈硬化治療剤 | |
Casato et al. | Idiopathic Mixed Cryoglobulinemia: A New Therapeutic Approach with Alpha Interferon | |
Pepys et al. | Role of the acute phase response in the Shwartzman phenomenon. | |
WO1993006853A1 (en) | Cell damage repairing factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NAL | Patent in force |
Ref document number: 8803472-3 Format of ref document f/p: F |
|
NUG | Patent has lapsed |
Ref document number: 8803472-3 Format of ref document f/p: F |